Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Cardiovascular disease is a major public health problem in our country. Among the causes of
cardiovascular diseases are High Blood Pressure (HBP) and Diabetes Mellitus (DM). Type 2
diabetes (DM2) is associated with a twofold risk of cardiovascular disease, and endothelial
dysfunction is an early marker of vascular complications. There is evidence of action of
glucagon-like peptide 1 (GLP-1) on endothelial cells and vascular smooth muscle. Vildagliptin
is a drug used in the treatment of DM2 able to prolong the activity of GLP-1, improving
glycemic control and endothelial function.
Objectives: To evaluate the effect of vildagliptin on endothelial function in patients with
DM2 and hypertension using the Endo-PAT 2000 device.